amring-company-hero

Our Company

is committed to promoting health across communities

What does Amring do?

Amring sells uniquely positioned and harder-to-manufacture generics that bring value to customers and patients.

We spend every minute of every day figuring out how to bring historically complex prescription medications to market. Our products are generics of value to the market, not high-volume, mass-produced products.

Contact us to partner

1935

Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.

1950

The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.

1954

The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.

1960

Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.

2015

Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.

2015

Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..

2016

Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.

2016

Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.

2017

Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.

2017

Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.

1935

Fredrik Paulsen eludes Gestapo to escape Nazi Germany and complete his medical studies in Basel, Switzerland.

1954

The company is re-named Ferring, in honor of the community on the Frisian island of Föhr, the ancestral home of the Paulsen family.

1960

Desmopressin, a modified version of vasopressin which mimics the action of vasopressin on the kidneys, is developed and eventually becomes Ferring’s first major breakthrough product.

2015

Desmopressin Acetate Tablets launches in U.S. and Amring is spun out as independent global entity under Arming Holding S.A..

2016

Amring U.S. exceeds goals with strong sales and grows pipeline through ANDA development and acquisitions.

2017

Amring closes the year with a 20% increase in sales over 2016 and a pipeline that has two (2) ANDAs filed with the FDA as well as the rights to market an ophthalmic medical device.

!

1950

The fledgling company is the only one able to supply ACTH to the pharmaceutical industry in quantity and to the quality standards.

2015

Amring is launched in EU and U.S. under a global healthcare umbrella. Amring commercial HQ and U.S. pipeline are established.

2016

Amring U.S. launches additional Desmopressin products including the Nasal Spray and Injection as well as Tranexamic Acid Tablets.

2017

Amring Group operations expand worldwide through licensing and acquisition deals. Global portfolio increases to include injection, sprays, tablets, biosimilars, and medical devices.

Amring is a proud member of the global pharmaceutical community.

Our strong global network of drug technology and manufacturing gives us the quality and regulatory capability to meet the demands of various niche markets.

Partner with us to offer Amring products

Contact us today